The size of the Apheresis Market worth in Europe was valued at USD 0.46 billion in 2020 and estimated to be growing at a CAGR of 8.74% to reach USD 0.7 billion by 2025.
Y-O-Y growth in the incidence of blood disorders such as bleeding disorders and a decrease in platelet count are expected to hike the European Apheresis Market's growth. The growing prevalence of chronic diseases such as cancer and autoimmune diseases, an increasing number of organ donors when needed, further adds fuel to the market's growth rate. Perforation in the occurrence rate of chronic diseases, increasing necessity for source plasma, mounting activities considering the blood safety and growing number of complicated surgical processes, and acceptance of reimbursement policies are projected to lavish the market's need from 2020 to 2025.
Shortage of capable donors, the high costs associated with the apheresis devices, expensiveness involved with the maintenance and installation of these devices are expected to hinder the market growth to a small extent.
This research report on the European Apheresis Market has been segmented and sub-segmented into the following categories:
By Product:
By Procedure:
By Application:
By Technology:
By End User:
By Country:
Regional Analysis:
In Europe, Germany leads the Apheresis market, followed by France and U.K. The market in this region is projected to grow strongly during the forecast period due to various factors such as growing awareness about Apheresis, financial strength to procure expensive tools, and favorable reimbursement policies. The European market has a share of 26% Global market. It has a CAGR of 8.74% owing to the presence of less stringent apheresis devices approval regulations and availability of massive untapped opportunities in emerging European countries.
The German apheresis market is anticipated to rule the European market during the forecast period owing to increasing consciousness regarding apheresis and economic strength to obtain high-priced devices. The escalating number of blood donations uses the apheresis devices, and augmenting the number of apheresis therapy procedures is predicted to drive Germany's market. The growing requirement for apheresis that can affect the lesser pathogens in platelets and components to reduce the threat of transfer-transmitted infections is further estimated to favor Germany's market.
France's apheresis market is expected to be another lucrative region in the European market and is anticipated to grow with a CAGR of 12.5% from 2020 to 2025. The rise in healthcare expenses, a huge patient population with a large transmission requirement, is majorly supporting the French market.
The UK market is the third leading country in the European market and is expected to grow at a brisk pace during the forecast period due to technological advancements.
Key players operating in the Europe Apheresis Market profiled in this report are Asahi Kasei Medical Co., Ltd., Haemonetics Corporation, Terumo BCT, Inc., Fresenius Medical Care, Kawasumi Laboratories Inc., Cerus Corporation, HemaCare Corporation, Kaneka Corporation, B. Braun Melsungen AG, and Nikkiso Co., Ltd., Therakos, Inc., and Medica S.p.A.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Product
5.1.1 Introduction
5.1.2 Apheresis devices
5.1.2.1 Plasma separators
5.1.2.2 Plasma component separators
5.1.2.3 Immunoadsorption Columns
5.1.2.4 Plasma Perfusion Columns
5.1.2.5 Hemoperfusion Columns
5.1.3 Apheresis disposables
5.1.4 Y-o-Y Growth Analysis, By Product
5.1.5 Market Attractiveness Analysis, By Product
5.1.6 Market Share Analysis, By Product
5.2 Procedure
5.2.1 Introduction
5.2.2 Donor Apheresis
5.2.3 Therapeutic Apheresis
5.2.4 Y-o-Y Growth Analysis, By Procedure
5.2.5 Market Attractiveness Analysis, By Procedure
5.2.6 Market Share Analysis, By Procedure
5.3 Application
5.3.1 Introduction
5.3.2 Renal Diseases
5.3.3 Neurology
5.3.4 Cancer
5.3.5 Hematology
5.3.6 Autoimmune Diseases
5.3.7 Cardiovascular Diseases
5.3.8 Y-o-Y Growth Analysis, By Application
5.3.9 Market Attractiveness Analysis, By Application
5.3.10 Market Share Analysis, By Application
5.4 Technology
5.4.1 Centrifugation
5.4.1.1 Intermittent Flow
5.4.1.2 Continuous Flow
5.4.2 Membrane Separation
5.4.3 Y-o-Y Growth Analysis, By Technology
5.4.4 Market Attractiveness Analysis, By Technology
5.4.5 Market Share Analysis, By Technology
5.5 End user
5.5.1 Introduction
5.5.2 Private Blood Collection Centres
5.5.3 Public Blood Collection Centres
5.5.4 Hospitals
5.4.5 Y-o-Y Growth Analysis, By End user
5.4.6 Market Attractiveness Analysis, By End user
5.4.7 Market Share Analysis, By End user
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Product
6.1.3.3 By Procedure
6.1.3.4 By Application
6.1.3.5 By Technology
6.1.3.6 By End user
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Product
6.1.4.3 By Procedure
6.1.4.4 By Application
6.1.4.5 By Technology
6.1.4.6 By End user
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Product
6.1.5.3 By Procedure
6.1.5.4 By Application
6.1.5.5 By Itechnology
6.1.5.6 By End user
6.2 U.K
6.3 Spain
6.4 Germany
6.5 Italy
6.6 France
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Asahi Kasei Medical Co., Ltd.
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Haemonetics Corporation
8.3 Terumo BCT, Inc.
8.4 Fresenius Medical Care
8.5 Kawasumi Laboratories Inc.
8.6 Cerus Corporation
8.7 Hemacare Corporation
8.8 Kaneka Corporation
8.9 Braun Melsungen AG
8.10 Nikkiso Co., Ltd.
8.11 Therakos, Inc.,
8.12 Medica S.p.A.
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
Feb 2020
